CA2151564A1 - Monomeric insulin analog formulations - Google Patents

Monomeric insulin analog formulations

Info

Publication number
CA2151564A1
CA2151564A1 CA002151564A CA2151564A CA2151564A1 CA 2151564 A1 CA2151564 A1 CA 2151564A1 CA 002151564 A CA002151564 A CA 002151564A CA 2151564 A CA2151564 A CA 2151564A CA 2151564 A1 CA2151564 A1 CA 2151564A1
Authority
CA
Canada
Prior art keywords
insulin analog
monomeric insulin
formulations
analog formulations
protamine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002151564A
Other languages
French (fr)
Other versions
CA2151564C (en
Inventor
Michael Rosario De Felippis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Michael Rosario De Felippis
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22989963&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2151564(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Michael Rosario De Felippis, Eli Lilly And Company filed Critical Michael Rosario De Felippis
Publication of CA2151564A1 publication Critical patent/CA2151564A1/en
Application granted granted Critical
Publication of CA2151564C publication Critical patent/CA2151564C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones

Abstract

The present invention discloses various parenteral pharmaceutical formulations, which comprise: a monomeric insulin analog, zinc, protamine, and phenolic derivative.
The analog formulations provide a prolonged duration of action. A process for preparing insulin analog-protamine formulations is also described.
CA002151564A 1994-06-16 1995-06-12 Monomeric insulin analog formulations Expired - Lifetime CA2151564C (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/260,633 1994-06-16
US08/260,633 US5461031A (en) 1994-06-16 1994-06-16 Monomeric insulin analog formulations

Publications (2)

Publication Number Publication Date
CA2151564A1 true CA2151564A1 (en) 1995-12-17
CA2151564C CA2151564C (en) 2003-02-11

Family

ID=22989963

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002151564A Expired - Lifetime CA2151564C (en) 1994-06-16 1995-06-12 Monomeric insulin analog formulations

Country Status (37)

Country Link
US (3) US5461031A (en)
JP (1) JP3812962B2 (en)
KR (1) KR100386038B1 (en)
CN (1) CN1145641C (en)
AT (1) AT408611B (en)
BE (1) BE1009409A5 (en)
BR (1) BR9502797A (en)
CA (1) CA2151564C (en)
CH (2) CH693019A5 (en)
CO (1) CO4410204A1 (en)
CZ (1) CZ294556B6 (en)
DE (1) DE19521753B4 (en)
DK (1) DK176213B1 (en)
ES (1) ES2091728B1 (en)
FI (1) FI118208B (en)
FR (1) FR2721215B1 (en)
GB (1) GB2290294B (en)
GR (1) GR1002494B (en)
HU (1) HU218943B (en)
IE (1) IE68852B1 (en)
IL (1) IL114153A (en)
IT (1) IT1276722B1 (en)
LU (1) LU88627A1 (en)
MY (1) MY116831A (en)
NL (2) NL1000565C2 (en)
NO (1) NO320808B1 (en)
NZ (1) NZ272360A (en)
PE (1) PE34496A1 (en)
PL (1) PL183284B1 (en)
PT (1) PT101723B (en)
RO (1) RO115124B1 (en)
SE (1) SE509295C2 (en)
SI (1) SI9500199A (en)
TW (1) TW347334B (en)
UA (1) UA34468C2 (en)
YU (1) YU39795A (en)
ZA (1) ZA954941B (en)

Families Citing this family (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5888477A (en) * 1993-01-29 1999-03-30 Aradigm Corporation Use of monomeric insulin as a means for improving the bioavailability of inhaled insulin
EP1607086A1 (en) * 1993-01-29 2005-12-21 Aradigm Corporation Method of use of monomeric insulin as a means for improving the reproducibility of inhaled insulin
US6131567A (en) * 1993-01-29 2000-10-17 Aradigm Corporation Method of use of monomeric insulin as a means for improving the reproducibility of inhaled insulin
US6024090A (en) * 1993-01-29 2000-02-15 Aradigm Corporation Method of treating a diabetic patient by aerosolized administration of insulin lispro
DK72793D0 (en) * 1993-06-21 1993-06-21 Novo Nordisk As NEW PRODUCT
US5461031A (en) * 1994-06-16 1995-10-24 Eli Lilly And Company Monomeric insulin analog formulations
US5547929A (en) * 1994-09-12 1996-08-20 Eli Lilly And Company Insulin analog formulations
AR002976A1 (en) * 1995-03-31 1998-05-27 Lilly Co Eli PARENTERAL PHARMACEUTICAL FORMULATIONS OF LONG-TERM EFFECT OF INSULIN; CRYSTALS OF SUCH ANALOGUES APPLICABLE IN SUCH FORMULATIONS AND PROCEDURE OF THE FORMULATIONS MENTIONED
EP0835129B1 (en) * 1995-06-30 2003-10-29 Novo Nordisk A/S Prevention of a disease having the characteristics of diabetes
BR9709845B1 (en) * 1996-06-20 2008-11-18 aqueous insulin preparation, parenteral pharmaceutical formulation, and process for enhancing the chemical stability of an insulin preparation.
DE69829953T2 (en) * 1997-02-07 2006-03-02 Novo Nordisk A/S CRYSTALLIZATION OF PROTEINS
US5898067A (en) * 1997-02-07 1999-04-27 Novo Nordisk A/S Crystallization of proteins
AR012894A1 (en) * 1997-06-13 2000-11-22 Lilly Co Eli FORMULATION OF INSULIN IN STABLE SOLUTION, ITS USE TO PREPARE A MEDICINAL PRODUCT AND PROCESS FOR THE PREPARATION OF THE SAME.
EP1283051B1 (en) * 1997-06-13 2006-06-14 Eli Lilly And Company Stable insulin formulations
PL340255A1 (en) * 1997-10-24 2001-01-29 Lilly Co Eli Non-dissolving insulin compositions
US6531448B1 (en) * 1997-12-23 2003-03-11 Eli Lilly And Company Insoluble compositions for controlling blood glucose
US20010053761A1 (en) * 1998-01-08 2001-12-20 Dimarchi Richard Dennis Method for administering aspb28-human insulin
US20040214747A1 (en) * 1999-01-06 2004-10-28 Dimarchi Richard Dennis Method for administering monomeric insulin
US6624141B1 (en) * 1999-03-17 2003-09-23 The Regents Of The University Of Michigan Protamine fragment compositions and methods of use
US7169889B1 (en) * 1999-06-19 2007-01-30 Biocon Limited Insulin prodrugs hydrolyzable in vivo to yield peglylated insulin
US7678364B2 (en) 1999-08-25 2010-03-16 Alkermes, Inc. Particles for inhalation having sustained release properties
EP1346726A4 (en) * 2000-12-25 2004-09-15 Shiseido Co Ltd Sympathetic-activating perfume composition
EP1772464B1 (en) * 2001-02-09 2009-08-12 Genentech, Inc. Methods of identifying indirect agonists of IGF-1
US7060675B2 (en) 2001-02-15 2006-06-13 Nobex Corporation Methods of treating diabetes mellitus
US6867183B2 (en) 2001-02-15 2005-03-15 Nobex Corporation Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
US6828305B2 (en) 2001-06-04 2004-12-07 Nobex Corporation Mixtures of growth hormone drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6835802B2 (en) * 2001-06-04 2004-12-28 Nobex Corporation Methods of synthesizing substantially monodispersed mixtures of polymers having polyethylene glycol moieties
US6858580B2 (en) * 2001-06-04 2005-02-22 Nobex Corporation Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6713452B2 (en) * 2001-06-04 2004-03-30 Nobex Corporation Mixtures of calcitonin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US7713932B2 (en) 2001-06-04 2010-05-11 Biocon Limited Calcitonin drug-oligomer conjugates, and uses thereof
US6828297B2 (en) 2001-06-04 2004-12-07 Nobex Corporation Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
WO2003020201A2 (en) * 2001-08-28 2003-03-13 Eli Lilly And Company Pre-mixes of glp-1 and basal insulin
US7196059B2 (en) 2001-09-07 2007-03-27 Biocon Limited Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
US7030082B2 (en) * 2001-09-07 2006-04-18 Nobex Corporation Pharmaceutical compositions of drug-oligomer conjugates and methods of treating disease therewith
US7166571B2 (en) 2001-09-07 2007-01-23 Biocon Limited Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US7312192B2 (en) 2001-09-07 2007-12-25 Biocon Limited Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US6770625B2 (en) 2001-09-07 2004-08-03 Nobex Corporation Pharmaceutical compositions of calcitonin drug-oligomer conjugates and methods of treating diseases therewith
US6913903B2 (en) 2001-09-07 2005-07-05 Nobex Corporation Methods of synthesizing insulin polypeptide-oligomer conjugates, and proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US20030068361A1 (en) * 2001-10-09 2003-04-10 Rimona Margalit Liposome-encapsulated insulin formulations
CN1571676A (en) * 2001-10-19 2005-01-26 伊莱利利公司 Biphasic mixtures of GLP-1 and insulin
AU2002346491A1 (en) * 2001-12-19 2003-07-09 Eli Lilly And Company Crystalline compositions for controlling blood glucose
AU2003236521A1 (en) * 2002-06-13 2003-12-31 Nobex Corporation Methods of reducing hypoglycemic episodes in the treatment of diabetes mellitus
US20060258561A1 (en) * 2003-03-13 2006-11-16 Novo Nordisk A/S Novel NPH insulin preparations
WO2004111244A2 (en) 2003-06-17 2004-12-23 Sembiosys Genetics Inc. Methods for the production of insulin in plants
US20050054818A1 (en) * 2003-07-02 2005-03-10 Brader Mark Laurence Crystalline compositions for controlling blood glucose
JP2007520441A (en) * 2003-07-25 2007-07-26 コンジュシェム，インコーポレイティド Persistent insulin derivatives and methods thereof
WO2005072803A1 (en) * 2004-01-16 2005-08-11 Biodel, Inc. Sublingual drug delivery device
US20080096800A1 (en) * 2004-03-12 2008-04-24 Biodel, Inc. Rapid mucosal gel or film insulin compositions
PT2319500E (en) * 2004-03-12 2013-01-23 Biodel Inc Rapid acting drug delivery compositions
US20080090753A1 (en) * 2004-03-12 2008-04-17 Biodel, Inc. Rapid Acting Injectable Insulin Compositions
US20080085298A1 (en) * 2004-03-12 2008-04-10 Biodel, Inc. Rapid Mucosal Gel or Film Insulin Compositions
WO2006014673A2 (en) 2004-07-19 2006-02-09 Nobex Corporation Insulin-oligomer conjugates, formulations and uses thereof
US7597884B2 (en) 2004-08-09 2009-10-06 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
AU2005273968A1 (en) * 2004-08-09 2006-02-23 Alios Biopharma Inc. Synthetic hyperglycosylated, protease-resistant polypeptide variants, oral formulations and methods of using the same
US7884181B2 (en) * 2004-10-05 2011-02-08 Novo Nordisk A/S Pharmaceutical formulation comprising crystalline insulin and dissolved insulin
US8263551B2 (en) 2004-11-22 2012-09-11 Novo Nordisk A/S Soluble, stable insulin-containing formulations with a protamine salt
US7833513B2 (en) 2004-12-03 2010-11-16 Rhode Island Hospital Treatment of Alzheimer's Disease
US8084420B2 (en) * 2005-09-29 2011-12-27 Biodel Inc. Rapid acting and long acting insulin combination formulations
US7713929B2 (en) * 2006-04-12 2010-05-11 Biodel Inc. Rapid acting and long acting insulin combination formulations
CN100371346C (en) * 2005-12-14 2008-02-27 浙江大学 Artificial synthesized insulin-simulated peptide and its application
WO2007096431A1 (en) * 2006-02-27 2007-08-30 Novo Nordisk A/S Insulin derivatives
WO2007121318A2 (en) 2006-04-12 2007-10-25 Emisphere Technologies, Inc. Formulations for delivering insulin
US7718609B2 (en) * 2006-04-12 2010-05-18 Biodel Inc. Rapid acting and long acting insulin combination formulations
CN101062948B (en) * 2006-04-29 2010-05-12 上海生物泰生命科学研究有限公司 Monomer quick-effective insulin and preparation method and usage thereof
WO2008124522A2 (en) * 2007-04-04 2008-10-16 Biodel, Inc. Amylin formulations
US20080260820A1 (en) * 2007-04-19 2008-10-23 Gilles Borrelly Oral dosage formulations of protease-resistant polypeptides
ES2664822T3 (en) 2007-10-16 2018-04-23 Biocon Limited A solid pharmaceutical composition orally administrable and a process thereof
CN101951957A (en) * 2008-01-04 2011-01-19 百达尔公司 Insulin discharges the insulin preparation as the function of the glucose level of tissue
WO2010028175A1 (en) 2008-09-08 2010-03-11 The Board Of Trustees Of The Leland Stanford Junior University Modulators of aldehyde dehydrogenase activity and methods of use thereof
JP2012506856A (en) 2008-10-28 2012-03-22 ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティ Modulator of aldehyde dehydrogenase and method of use thereof
AU2010208305A1 (en) 2009-01-28 2011-09-08 Smartcells, Inc. Synthetic conjugates and uses thereof
MA33064B1 (en) * 2009-01-28 2012-02-01 Smartcells Inc Concomitant drug control management system
MX2011008562A (en) 2009-02-12 2011-09-09 Proyecto Biomedicina Cima Sl Use of cardiotrophin- 1 for the treatment of metabolic diseases.
US9060927B2 (en) * 2009-03-03 2015-06-23 Biodel Inc. Insulin formulations for rapid uptake
JP2012520879A (en) 2009-03-20 2012-09-10 スマートセルズ・インコーポレイテツド End-functionalized conjugates and uses thereof
HUP0900482A2 (en) * 2009-08-03 2011-03-28 Cera Med Kft Pharmaceutical formulation for oral administration
AU2011282988A1 (en) 2010-07-28 2013-01-31 Smartcells, Inc. Recombinantly expressed insulin polypeptides and uses thereof
AU2011336896B2 (en) * 2010-11-24 2015-12-24 Durect Corporation Biodegradable drug delivery composition
US20140011733A1 (en) 2011-01-20 2014-01-09 Zealand Pharma A/S Combination of acylated glucagon analogues with insulin analogues
US10457659B2 (en) 2011-04-29 2019-10-29 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for increasing proliferation of adult salivary stem cells
CA2890048C (en) 2012-12-03 2022-05-03 Merck Sharp & Dohme Corp. O-glycosylated carboxy terminal portion (ctp) peptide-based insulin and insulin analogues
KR20150135332A (en) 2013-03-14 2015-12-02 더 보드 오브 트러스티스 오브 더 리랜드 스탠포드 쥬니어 유니버시티 Mitochondrial aldehyde dehydrogenase-2 modulators and methods of use thereof
EP3052134B1 (en) 2013-10-04 2021-05-05 Merck Sharp & Dohme Corp. Glucose-responsive insulin conjugates
JP6564369B2 (en) 2013-12-09 2019-08-21 デュレクト コーポレイション Pharmaceutically active agent conjugates, polymer conjugates, and compositions and methods involving them
MX2016008978A (en) * 2014-01-09 2016-10-04 Sanofi Sa Stabilized glycerol free pharmaceutical formulations of insulin analogues and/or insulin derivatives.
BR112016016290A2 (en) 2014-01-13 2017-10-03 Thermalin Diabetes Llc PHARMACEUTICAL COMPOSITIONS OF FAST-ACTING INSULIN, INFUSION SET, INFUSION SET SYSTEM AND USES OF MONOMER OR DIMERIC INSULIN ANALOGS
AR099569A1 (en) 2014-02-28 2016-08-03 Novo Nordisk As INSULIN DERIVATIVES AND THE MEDICAL USES OF THESE
DK3006045T3 (en) 2014-10-07 2017-07-17 Cyprumed Gmbh Pharmaceutical formulations for oral administration of peptide or protein drugs
WO2017163159A1 (en) 2016-03-21 2017-09-28 Wockhardt Limited Biphasic pharmaceutical composition of insulin human
JP6633777B2 (en) 2017-08-24 2020-01-22 ノヴォ ノルディスク アー／エス GLP-1 compositions and uses thereof
US11110063B2 (en) 2017-08-25 2021-09-07 MAIA Pharmaceuticals, Inc. Storage stable sincalide formulations
WO2019125879A2 (en) 2017-12-18 2019-06-27 Merck Sharp & Dohme Corp. Conjugate based systems for controlled insulin delivery
EP3727424A4 (en) 2017-12-18 2021-10-27 Merck Sharp & Dohme Corp. Conjugate based systems for controlled insulin delivery
CN110063932A (en) * 2019-04-12 2019-07-30 浙江大学 A kind of slow releasing composition preparation of polypeptide protein class drug and preparation method thereof
US11318191B2 (en) 2020-02-18 2022-05-03 Novo Nordisk A/S GLP-1 compositions and uses thereof
WO2021202802A1 (en) 2020-03-31 2021-10-07 Protomer Technologies Inc. Conjugates for selective responsiveness to vicinal diols
PE20231948A1 (en) 2020-11-19 2023-12-05 Protomer Tech Inc AROMATIC COMPOUNDS CONTAINING BORON AND INSULIN ANALOGUES
WO2023225534A1 (en) 2022-05-18 2023-11-23 Protomer Technologies Inc. Aromatic boron-containing compounds and related insulin analogs

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2538018A (en) * 1944-04-04 1951-01-16 Nordisk Insulinlab Crystalline product of insulin and alkaline protein and process of making it
US2801953A (en) * 1952-02-28 1957-08-06 Hoechst Ag Process of preparing crystallized insulin preparations
US2849370A (en) * 1953-06-04 1958-08-26 Novo Terapeutisk Labortorium A Injectable insulin preparations with protracted effect and process of producing same
US3060093A (en) * 1957-07-18 1962-10-23 Nordisk Insulinlab Slowly acting insulin preparation in crystalline form and method of preparation
US3868358A (en) * 1971-04-30 1975-02-25 Lilly Co Eli Protamine-insulin product
DE3326473A1 (en) * 1983-07-22 1985-01-31 Hoechst Ag, 6230 Frankfurt PHARMACEUTICAL AGENT FOR TREATING THE DIABETES MELLITUS
DE3327709A1 (en) * 1983-07-29 1985-02-07 Hoechst Ag, 6230 Frankfurt INSULIN DERIVATIVE CRYSTAL SUSPENSIONS, METHOD FOR THE PRODUCTION AND USE THEREOF
DK119785D0 (en) * 1985-03-15 1985-03-15 Nordisk Gentofte INSULIN PREPARATION
PH25772A (en) * 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
IE62879B1 (en) * 1987-02-25 1995-03-08 Novo Nordisk As Novel insulin derivatives
DE3717370A1 (en) * 1987-05-22 1988-12-01 Hoechst Ag MIXED CRYSTALS FROM INSULIN AND INSULINE DERIVATIVES, METHOD FOR THE PRODUCTION OF THESE MIXED CRYSTALS, PHARMACEUTICAL AGENTS CONTAINING THESE MIXED CRYSTALS AND THEIR USE FOR TREATING DIABETES MELLITUS
JPH03506023A (en) * 1988-07-20 1991-12-26 ノボ　ノルデイスク　アクツイエセルスカプ polypeptide
AU641631B2 (en) * 1988-12-23 1993-09-30 Novo Nordisk A/S Human insulin analogues
US5514646A (en) * 1989-02-09 1996-05-07 Chance; Ronald E. Insulin analogs modified at position 29 of the B chain
NZ232375A (en) * 1989-02-09 1992-04-28 Lilly Co Eli Insulin analogues modified at b29
DE10199011I2 (en) * 1993-06-21 2004-10-14 Novo Nordisk As ASP-B28-insulin crystals.
DK72793D0 (en) * 1993-06-21 1993-06-21 Novo Nordisk As NEW PRODUCT
US5461031A (en) * 1994-06-16 1995-10-24 Eli Lilly And Company Monomeric insulin analog formulations
US5474978A (en) * 1994-06-16 1995-12-12 Eli Lilly And Company Insulin analog formulations

Also Published As

Publication number Publication date
FI952932A (en) 1995-12-17
GB2290294B (en) 1999-03-17
SE9502168D0 (en) 1995-06-14
US5461031A (en) 1995-10-24
IL114153A (en) 2000-09-28
PT101723A (en) 1995-12-29
US5650486A (en) 1997-07-22
NO952356D0 (en) 1995-06-14
FI118208B (en) 2007-08-31
KR960000923A (en) 1996-01-25
CH693019A5 (en) 2003-01-31
NO320808B1 (en) 2006-01-30
CA2151564C (en) 2003-02-11
NL1000565A1 (en) 1995-12-18
HU9501717D0 (en) 1995-08-28
IL114153A0 (en) 1995-10-31
GB9512105D0 (en) 1995-08-09
MY116831A (en) 2004-04-30
YU39795A (en) 1998-05-15
DK176213B1 (en) 2007-02-12
ZA954941B (en) 1996-12-17
BE1009409A5 (en) 1997-03-04
BR9502797A (en) 1996-03-12
PT101723B (en) 1997-02-28
NL1004643C2 (en) 1997-02-12
UA34468C2 (en) 2001-03-15
DK67695A (en) 1995-12-17
NZ272360A (en) 1997-02-24
SE509295C2 (en) 1999-01-11
JPH083064A (en) 1996-01-09
RO115124B1 (en) 1999-11-30
FR2721215B1 (en) 1997-08-14
NO952356L (en) 1995-12-18
SI9500199A (en) 1996-02-29
CZ154395A3 (en) 1996-02-14
CO4410204A1 (en) 1997-01-09
CZ294556B6 (en) 2005-02-16
AT408611B (en) 2002-01-25
ES2091728B1 (en) 1998-02-01
SE9502168L (en) 1995-12-17
CN1116629A (en) 1996-02-14
IE68852B1 (en) 1996-07-24
DE19521753B4 (en) 2009-07-23
US5747642A (en) 1998-05-05
LU88627A1 (en) 1996-02-01
IE950435A1 (en) 1995-12-27
GB2290294A (en) 1995-12-20
PE34496A1 (en) 1996-10-01
PL183284B1 (en) 2002-06-28
ATA101795A (en) 2001-06-15
DE19521753A1 (en) 1995-12-21
HUT71908A (en) 1996-02-28
GR1002494B (en) 1996-12-12
FR2721215A1 (en) 1995-12-22
NL1004643A1 (en) 1996-12-17
IT1276722B1 (en) 1997-11-03
ITMI951277A0 (en) 1995-06-14
ITMI951277A1 (en) 1996-12-14
TW347334B (en) 1998-12-11
PL309100A1 (en) 1995-12-27
NL1000565C2 (en) 1996-12-03
ES2091728A1 (en) 1996-11-01
HU218943B (en) 2001-01-29
FI952932A0 (en) 1995-06-14
JP3812962B2 (en) 2006-08-23
CH689934A5 (en) 2000-02-15
CN1145641C (en) 2004-04-14
KR100386038B1 (en) 2003-08-27

Similar Documents

Publication Publication Date Title
CA2151564A1 (en) Monomeric insulin analog formulations
EP1090640A3 (en) Insulin analog formulations
ZA962502B (en) Monomeric insulin analog formulations.
AU691361B2 (en) Novel 2,3-diketopiperazine derivative or salt thereof
CA2151560A1 (en) Insulin Analog Formulations
AU6627990A (en) Biosignal electrode
AU4642393A (en) Medication sprayer
AU3299293A (en) New pyrethrinoid esters derived from thiazolic alcohols, their preparation process and their use as pesticides
AU5229690A (en) Polyamide 4.6 composition
AU3263493A (en) Tonometer
AU8388691A (en) Substituted 1,2,4-triazinediones, processes for their preparation, intermediates therefor and their use
AU673401B2 (en) 6,7-dialkoxy-3,4-dihydroisoquinolin-8-ol, process for preparation thereof and process for preparation of 6,7-dialkoxy-1,2,3,4-tetrahydroisoquinolin-8-ol using the compound
AU3709689A (en) Substituted 4-sulphonylamino-2-azinyl-1,2,4-traizol-3-ones, processes and intermediates for their preparation and their use as herbicides
AU5388090A (en) N-sulfenyl- and n-sulfinyl-n,n'-diacylhydrazides
AU6511294A (en) Tonometer
AU5808294A (en) A process for the preparation of 2,3,5,6-tetrachloropyridine
AU9198698A (en) Process for the preparation of substituted 5,6-dihydro-2h-pyran-2-ones
AU8482791A (en) Cyclohexane oxidation
AU4762993A (en) Keratometer
AU5066693A (en) Process for the preparation of 5,6-diacetoxyindole
AU1681895A (en) Process for preparing 4,4-dialkyl-6-halo-chromans or thiochromans useful as pharmaceutical intermediates
AU595786B3 (en) Spray head assembly
AU677262B2 (en) N-acyl-n-phenylmaleamic acid derivative, process for producing the same, and herbicide containing the same as active ingredient
AU666799B2 (en) N-aryloxyacyl-n-phenyltetrahydrophthalamic acid derivative, process for producing the same, and herbicide containing the same as active ingredient
AU684260B2 (en) 1,4-benzoxazine-2-acetic acid compound, process for producing the same, and use thereof

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20150612